Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical outcome, toxicity and organ/function preservation.
Mantovani G, Maccio A, Massa E, Mulas C, Mudu MC, Massidda S, Massa D, Murgia V, Ferreli L, Succu G, Astara G, Proto E, Tore G, Mura M, Maxia G. Mantovani G, et al. Among authors: massa e, massa d. Int J Oncol. 2000 Jun;16(6):1227-33. doi: 10.3892/ijo.16.6.1227. Int J Oncol. 2000. PMID: 10812000 Clinical Trial.
Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G, Ghiani M, Lai P, Maccio A, Dessi D, Succu G, Massa D, Curreli L, Mulas C, Esu S, Proto E, Cadeddu G, Tore G. Mantovani G, et al. Among authors: massa d. Oncol Rep. 1998 Nov-Dec;5(6):1499-505. doi: 10.3892/or.5.6.1499. Oncol Rep. 1998. PMID: 9769395 Clinical Trial.
Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: clinical response and organ/function preservation.
Mantovani G, Macciò A, Massa E, Mulas C, Mudu MC, Massidda S, Massa D, Murgia V, Ferreli L, Succu G, Astara G, Proto E, Tore G, Mura M, Maxia G. Mantovani G, et al. Among authors: massa e, massa d. Oncol Rep. 1999 Nov-Dec;6(6):1425-30. doi: 10.3892/or.6.6.1425. Oncol Rep. 1999. PMID: 10523724 Clinical Trial.
Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
Mantovani G, Curreli L, Macciò A, Massa E, Massa D, Mulas C, Succu G, Contu P. Mantovani G, et al. Among authors: massa e, massa d. Anticancer Res. 1999 Jul-Aug;19(4C):3495-502. Anticancer Res. 1999. PMID: 10629642 Clinical Trial.
Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer.
Mantovani G, Macciò A, Lai P, Massa E, Massa D, Mulas C, Succu G, Mudu MC, Manca G, Versace R, Pisano A. Mantovani G, et al. Among authors: massa e, massa d. J Immunother. 2000 Mar-Apr;23(2):267-74. doi: 10.1097/00002371-200003000-00011. J Immunother. 2000. PMID: 10746553 Clinical Trial.
98 results